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Background:  Currently,  testing  on HPV  in oropharyngeal  squamous  cell  carcinoma  (OPSCC)  is performed
on  histological  material.  However,  in  a certain  percentage  of the  cases  who  present  with  lymph  node
metastases  no  primary  tumor  can  be identiﬁed  and  only  ﬁne  needle  aspiration  cytology  (FNAC)  is available
for  analysis.
Objectives:  Purpose  of this  study  was  to  assess  HPV  status  on  FNAC  and  to validate  it using  histological
material  of  the same  patients.
Study  design:  Patients  with  cervical  metastasis  from  OPSCC  or  cancer  of an  unknown  primary  tumor
(CUP),  diagnosed  between  2007  and  2012  were  included.  In  6  of  the 47  patients,  no  primary  tumor  could
be  identiﬁed.  HPV  detection  and genotyping  was  performed  in  both  FNAC  slides  scrapings  and  formalin
ﬁxed  parafﬁn  embedded  (FFPE)  histological  material  from  the  same  patients,  using  the  HPV  SPF10-LiPA25
assay.  HPV  PCR  analysis  on  FFPE  material  was  considered  the  reference  standard  for  HPV  status  of  each
case.
Results: Compared  with  HPV  negative  cases  (n =  22),  signiﬁcantly  more  HPV  positive  cases  (n =  25)  pre-
sented  initially  with  cervical  metastasis  (27%  vs  56%  respectively;  p = 0·047).  The  HPV  PCR  assay  on  FNAC
material  showed  a high  sensitivity  (96%;  95%  CI 86.6–97.4)  and  speciﬁcity  (100%;  95%  CI 85.1–96.7)  using
the  reference  standard  of HPV  PCR  analysis  on FFPE  material  of  the  same  patients.
Conclusion:  In  this  study,  testing  on HPV  in  FNAC  of  cervical  lymph  node  metastases  of  SCC  is  vali-
dated.  It provides  a valuable  alternative  for testing  of  HPV  on  histological  material  from  patients  with
oropharyngeal  squamous  cell  carcinoma  or  cancer  of an  unknown  primary  tumor.
©  2016  The  Authors.  Published  by Elsevier  B.V. This  is  an open  access  article  under  the  CC BY  license
(http://creativecommons.org/licenses/by/4.0/).
1. Background
In the last decade it became evident that viral integration of
high-risk human papillomavirus (hrHPV) types, especially HPV
type 16, is an important factor in the oncogenesis of oropharyngeal
squamous cell carcinoma (OPSCC) [1,2]. Through overexpression
Abbreviations: CUP, cancer of an unknown primary tumor; FNAC, ﬁne needle
aspiration cytology; HPV, Human papilloma virus; OPSCC, oropharyngeal squamous
cell carcinoma.
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of the HPV oncoproteins E6 and E7, as a result of disruption of
E2 after HPV-DNA integration into the host DNA, the host tumor-
suppressor proteins p53 and retinoblastoma (Rb) are degraded.
This subsequently leads to p53 dysfunction and p16INK4A upregula-
tion [3,4]. This mechanism is responsible for the distinct molecular,
clinical and pathological entity of HPV-related OPSCC as compared
with HPV-unrelated tumors, which are associated with alcohol and
smoking habits [1,5]. The prevalence of HPV-related OPSCC is ris-
ing and reported with a reported wide range between 20% and 90%
[6,7].
It has become evident that HPV-positive OPSCCs patients have
a better survival outcome with a signiﬁcant reduction in mortal-
ity in comparison with patients with HPV negative tumors. This
is thought to be partly due to a favorable response to ionizing
http://dx.doi.org/10.1016/j.jcv.2016.10.008
1386-6532/© 2016 The Authors. Published by Elsevier B.V. This is an open access article under the CC BY license (http://creativecommons.org/licenses/by/4.0/).
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radiation and chemotherapy regimes, attributed to an intact p53
apoptosis pathway [8,9]. Therefore, HPV status has become a major
prognostic factor in patients with OPSCC.
Despite extensive diagnostic workup, including a thorough clin-
ical and endoscopical examination with the taking of biopsies and
the use of several imaging techniques, two to ﬁve percent of cases
who present with neck nodes containing metastatic SCC remain
with an unidentiﬁed primary site of origin [10,11]. This is thought
to be due to a possible involution of the primary tumor or a slow
growth rate of the primary tumor as compared to their metastases,
resulting in a very small and undetectable primary tumor with a
more advanced N-stage [5]. In particular in case of a primary loca-
tion in the tonsillar crypts and the base of the tongue such a small
primary tumor may  remain undetected. So it may  be hypothesized
that at least a part of the patients with cancer of an unknown
primary tumor (CUP) could in fact suffer from small undetected
OPSCCs. Therefore, important diagnostic and prognostic informa-
tion can be expected to be provided by the HPV status of the cancer
cells in CUP, as it may  point towards the most likely site of origin of
the primary tumor in case of HPV-positivity, namely the orophar-
ynx. Testing on HPV in this category of patients with CUP to localize
the primary tumor site in the oropharynx is an accepted concept
now.
Currently, the HPV status of OPSCC is commonly determined
through the accepted algorithm of HPV detection by PCR combined
with p16 immunohistochemical (IHC) staining on histological
tumor material [12,13]. However, in case of CUP, no histological
material of a primary tumor is available for HPV analysis. If HPV
status can be reliably established by testing on material obtained by
ﬁne needle aspiration cytology (FNAC) of metastatic lymph nodes,
it can be used to locate the likely origin of the primary HNSCC in
CUP without the necessity to obtain material from a neck dissection
specimen.
To validate if testing on cytological material matches with test-
ing on histological material, we evaluated HPV-PCR analysis in
FNAC from cervical lymph node metastasis and compared it to the
golden standard of HPV-PCR on histological material from the same
patients. Although HPV analysis in FNAC material has been reported
previously, the validation using histological material of the same
patients has not been done before as far as we are aware of.
2. Study design
2.1. Case selection
FNAC samples obtained from metastatic lymph nodes of
patients diagnosed with OPSCC or CUP of the head and neck diag-
nosed between 2007 and 2012 were identiﬁed and retrieved from
the ﬁles of the Department of Pathology of the Radboud Univer-
sity Medical Center in Nijmegen, The Netherlands. Formalin ﬁxed
parafﬁn embedded (FFPE) histological material taken from the pri-
mary tumor or metastatic lymph node of the corresponding cases
was retrieved as well.
Cases were included if the FFPE material was both HPV and p16
IHC negative or both HPV and p16 IHC positive. p16 IHC was consid-
ered positive in cases that showed both diffuse and intense nuclear
and cytoplasmic staining in almost all tumor cells. Exclusion crite-
ria were: a second primary tumor in the head and neck region to
avoid uncertainty about the relationship between primary tumor
and metastasis, insufﬁcient cytological material for processing, and
previous exposure of the neck to radiotherapy.
Patient medical records were reviewed to document the pri-
mary tumor site, metastatic lymph node location and general
histopathological characteristics of the samples.
2.2. Tissue preparation and DNA puriﬁcation
The detection and genotyping of HPV was  performed on scraped
FNAC material from archival slides. The FNAC slides were reviewed
for determining tumor cell density and representativeness. After
soaking in xylene to remove the coverglass, the cytological mate-
rial on the slides was completely scraped off and transferred into
200 L phosphate buffered saline (PBS) suspension. Isolation and
puriﬁcation of the DNA was  performed with MagNa pure 96 (Roche
Molecular Diagnostics). The puriﬁed DNA was diluted in 50 L in
elution buffer (Roche Molecular Diagnostics) and stored in −20 ◦C
until further processing by PCR. In the process, internal extrac-
tion and ampliﬁcation controls were included to ensure a valid en
reliable procedure.
DNA was isolated from FFPE tissue sections (4 M)  with the
EZ1 robot (Qiagen, Germany, with the DNA tissue kit of Qiagen)
according to standard procedures [14] and used for PCR analysis. A
negative water control was  included with each batch of 10 samples.
2.2.1. HPV-DNA detection and typing
Broad-spectrum HPV-DNA ampliﬁcation was performed using a
short-PCR-fragment assay (HPV SPF10-LiPA25, version 1; Labo Bio-
medical Products B.V, Rijswijk, Netherlands). This assay ampliﬁes a
65-bp fragment of the L1 open reading frame of HPV genotypes, as
described by Melchers et al. [14] HPV genotyping was performed
using a cocktail of 9 conservative probes in a micro titer hybridiza-
tion assay, the DNA enzyme immunoassay (DEIA). The samples
positive for HPV by DEIA were then analyzed with the line probe
assay (LiPA25) by reverse hybridization with type-speciﬁc probes
for HPV 6, 11, 16, 18, 31, 33, 34, 35, 39, 40, 42, 43, 44, 45, 51, 52,
53, 54, 56, 58, 59, 66, 68/73, 70, and 74. The LiPA strips were visu-
ally inspected and interpreted following the standardized reference
guide. Phocine Herpesvirus (PhHV) was used as an internal control
for ampliﬁcation.
2.2.2. Statistical analysis
Pathological and clinical characteristics were assessed using a
contingency table 2 tests. By applying cross tabulation sensitivity,
speciﬁcity, positive predictive value and negative predictive value
were calculated (and 95% conﬁdence intervals (CI)) for ﬁnal HPV 16
classiﬁcations compared with the ‘golden standard’. Cohen  was
used to analyze the measure of agreement between histological
and cytological HPV analysis by means of SPF-10 assay. Statistical
analysis was  conducted using the statistical software package SPSS
20.0 (IBM corporation, 2011).
3. Results
3.1. Clinical and pathological characteristics
In our institute approximately 100 OPSCCs and 10 CUPs are diag-
nosed and treated annually. Based on the availability of histological
material already tested on HPV (in routine practice) and the avail-
ability of complementary FNAC material of these cases a selection
was made. The inclusion criteria were met  by 47 cases. In total, 25
HPV 16 positive cases and 22 HPV negative cases were included
for analysis. Compared with HPV negative cases (n = 22), signiﬁ-
cantly more HPV positive cases (n = 25) presented initially with a
metastasis to a regional lymph node (27.3% vs 56% respectively;
p = 0.047).
The characteristics of both groups are presented in Table 1. The
mean ages of both cohorts was  similar (mean 57.7 years vs. 58.4
years; p = 0.4) as well as the distribution of gender in the two groups
(p = 0.36). No clear difference in primary location between the two
groups was  observed (p = 0.48). Twenty cases presented initially
with SCC in the neck only. In six out of the total of 47 cases (13%) no
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Table 1
Patient group and histological characteristics.
Variables HPV positive (%)a HPV negative (%)b Total (%) p-value
N  = 25 N = 22 N = 47
Gender
− Male 6 (24%) 14 (64%) 33 (70%) 0.355
−  Female 19 (76%) 8 (36%) 14 (30%)
Age
−  Mean 57.7 yr 58.4 yr 58.0 yr 0.432
−  Range 34.6–77.3 yr 28.9–71.3 yr 28.9–77.2 yr
Tumor stagec
− T0 4 (16%) 2 (9%) 6 (13%) 0.129
−  T1 5 (20%) 2 (9%) 7 (15%)
−  T2 11 (44%) 5 (23%) 16 (34%)
−  T3 4 (16%) 7 (32%) 11 (23%)
−  T4 1 (4%) 6 (27%) 7 (15%)
Nodal  stagec
−N0 1 (4%) 1 (5%) 2 (4%) 0.718
−  N1 3 (12%) 4 (18%) 7 (15%)
−  N2 21 (84%) 17 (77%) 38 (81%)
− N2a 1 (4%) 3 (14%) 4 (9%)
− N2b 11 (44%) 7 (32%) 18 (38%)
− N2c 9 (36%) 7 (32%) 16 (34%)
−  N3 0 (0%) 0 (0%) 0 (0%)
Anatomical primary side tumor
− Tonsils 11 (44%) 8 (36%) 19 (40%) 0.484
−  Base of the tongue 8 (32%) 4 (18%) 12 (26%)
−  Cancer of Unknown Origin 4 (16%) 2 (9%) 6 (13%)
−  Other sites in the oropharynxd 2 (8%) 8 (36%) 10 (21%)
Origin tested FFPE material
− Tonsils 12 (48%) 9 (41%) 21 (45%) 0.361
−  Base of the tongue 6 (24%) 3 (14%) 9 (19%)
−  Neck dissection preparation 5 (20%) 2 (9%) 7 (15%)
−  Other sites in the oropharynxe 2 (8%) 8 (36%) 10 (21%)
Histological tumor differentiation
− Poor 2 (8%) 4 (18%) 7 (15%)
−  Moderate 19 (76%) 14 (64%) 33 (70%)
−  Well 3 (12%) 1 (5%) 3 (6%)
−  Unknown 1 (4%) 3 (14%) 4 (9%) 0.718
a Presence of HPV deﬁned as both HPV PCR and p16 IHC positive in FFPE material.
b Absence of HPV deﬁned as both HPV PCR and p16 IHC negative in FFPE material.
c Staging by American Joint Committee for Cancer (AJCC) TNM-staging oropharyngeal cancer, 7th edition, 2010.
d Other primary tumor sides: Soft palate 3 (67%), unknown location oropharynx 3 (6%), Vallecula 4 (8%).
e Other locations derived FFPE material: Soft palate 3 (6%); Vallecula 4 (8%); Unknown location oropharynx 3 (6%).
Table 2
Cytological scraped material characteristics.
Variables HPV positive (%)a HPV negative (%)b Total (%)
N  = 25 N = 22 N = 47
Neck level lymph node aspiration
− Level 2 14 (56%) 17 (77%) 31 (66%)
−  Level 3 0 (0%) 2 (9%) 2 (4%)
−  Level 4 2 (8%) 0 (0%) 2(4%)
−  Otherc 9 (36%) 3 (13%) 12 (26%)
Ultrasound guided FNA cytology
− Yes 23 (92%) 22 (100%) 45 (96%)
−  No 0 (0%) 0 (0%) 0 (0%)
−  Unknown 2 (8%) 0 (0%) 2 (4%)
Tumor  cell count cytological slides
− Sufﬁcient 21 (84%) 20 (91%) 40 (85%)
−  Low tumor cell countd 4 (16%) 3 (9%) 7 (15%)
Cytological staining
− Giemsa 25 (100%) 17 (77%) 42 (89%)
−  Papanicolaou 0 (0%) 5 (23%) 5 (11%)
a Presence of HPV deﬁned as both HPV PCR and p16 IHC positive in FFPE material.
b Absence of HPV deﬁned as both HPV PCR and p16 IHC negative in FFPE material.
c Other locations FNAC: Level 1: 1 (2%); Level 5: 2 (4%); Unknown level: 9 (10%).
d Low tumor cell count, but found sufﬁcient for analysis. Screened by a pathologist.
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Table  3
HPV Discrepancy analysis.
HPV status
SPF-10 FFPE
HPV Status
SPF-10 FNAC
Tumor cell count
FNA biopsy sample
Origin FFPE After retesting
SPF-10 FFPE
After retesting
SPF-10 FNAC
Case 21 HPV 16 HPV 16/33 Sufﬁcient tumor cell count Base of the tongue HPV 16 HPV 16
Case  23 HPV 16 – Sufﬁcient tumor cell count Base of the tongue No 2nd available –
Case  42 – HPV 33 Sufﬁcient tumor cell count Base of the tongue No 2nd available HPV 33
Case  48 – HPV 33 Sufﬁcient tumor cell count Tonsil – HPV 33
In four cases, there was a mismatch in HPV detection or classiﬁcation. All samples had a sufﬁcient tumor cell load and all FFPE materials were derived from the primary
tumor  location.
primary tumor site could be identiﬁed despite extensive work-up
and they remained CUP. In 40 cases both histological data from the
primary location and cytological material from metastatic lymph
nodes were available. In seven cases histology was available from
the neck dissection specimen. The characteristics of the cytological
material are summarized in Table 2.
3.2. HPV analysis
HPV-DNA analysis on cytological material matched with the
HPV status in 24 of the 25 cases positive for HPV analyzed on
FPPE material, resulting in sensitivity of 96%. Case 21 contained an
additional HPV type (HPV 33) in the FNAC. Retesting this sample
showed only positivity for HPV 16 (Table 3). One case (case 23) in
the FFPE HPV positive group was HPV negative on FNAC testing and
remained negative after retesting the sample (Table 3). This sample
contained sufﬁcient tumor cell for analysis.
None of the 22 p16 IHC and FFPE HPV negative cases were found
positive for HPV 16 in the FNAC (100%). So there were no false pos-
itive tests on FNAC, resulting in a speciﬁcity of 100%. Agreement
between both test assays was high. ( = 0.806; p < 0.001).
4. Discussion
In this study the test characteristics of HPV analysis in cyto-
logical material obtained by FNA from a metastatic lymph node
in patients with HNSCC by using the HPV status on histological
material as a gold standard were tested. With a sensitivity of 96%
and speciﬁcity of 100% and equally strong PPV and NPV (92%, 100%
respectively), this test proves to be useful in the management of
patients with cervical lymph node metastasis from an OPSCC or
from a CUP. In the latter cases this is particularly relevant as the pos-
sibility of HPV analysis on cytological material would be the only
option to establish the HPV status in the absence of biopsy material
from a primary tumor. Depending on HPV status, and therefore the
likelihood of an occult oropharyngeal origin, decisions on the pri-
mary treatment modality (surgery or radiotherapy) and inclusion
of the ipsilateral oropharynx in the radiation target volume, can de
made for those patients. Moreover, similar to patients with OPSCC,
it is likely to give prognostic information.
Previous studies have shown that determination of HPV status
based on FNAC can indicate the primary site of origin [15,16]. These
studies showed that the presence of HPV in HNSCC material points
towards a primary tumor location in the oropharynx. It has also
already been demonstrated that HPV-DNA is present in the metas-
tases of HPV-related primary tumors. This can be explained by
the fact that HPV-DNA is incorporated in human host DNA, before
the malignant process is activated [2]. However, these studies did
not validate the HPV analysis on cytological material of lymph
node metastasis using traditional HPV testing on histological biopsy
material as a gold standard as was the goal of the current study.
Different PCR assays are available to determine HPV status
in oropharyngeal carcinomas. Commonly used assays are the
GP5+/GP6+ PCR assay and the broad-spectrum SPF-10 PCR assay.
Even though both tests have high test qualities, there is a marked
difference in sensitivity with the SPF-10 test used in this study
having a higher sensitivity [14,17]. This might lead to different
analytical and clinical sensitivity and speciﬁcity of the test [18].
Although it could be expected that material derived from
metastatic lymph nodes would only contain HPV from a metastatic
process and therefore contains only the HPV DNA from the origi-
nal primary tumor, one FNAC sample (case 21) contained also HPV
33. As this HPV type was  not apparent in the retest run, the viral
load was probably very low (high analytical sensitivity of this PCR
assay) and may  imply a non-clinically relevant infection [17]. The
same was  found in two OPSCC cases HPV negative in the testing on
FFPE (cases 42 and 48) that were found positive for HPV 33 in the
FNAC analysis.
An algorithm including both staining for p16 and detection of
HPV is often used to establish HPV status and the use of p16 IHC
as ﬁrst step in the screening of HPV presence has been proposed
[13,19,20]. Studies of Schache et al. and Smeets et al. [13,19] have
shown that this algorithm has a very high sensitivity and speciﬁcity
(sensitivity 97% and 100%, speciﬁcity 94% and 100% respectively).
In the current study, cytological cell blocks were not available for
further p16 IHC staining. However, a similar algorithm could be
feasible in analysis of cytological samples obtained from cervical
neck nodes, at ﬁrst doing p16 IHC on histologically processed cyto-
logical material and thereafter, in case of p16 expression, further
evaluation by PCR.
Besides diagnostic and prognostic beneﬁts, determining the
HPV status in cytological material could be used for treatment
stratiﬁcation depending on HPV status with the objective to
obtain optimal oncologic outcome paired with decreased treatment
related toxicity and morbidity. Various studies have retrospec-
tively shown relatively better locoregional control rates with
(chemo)radiotherapy in patients with HPV positive tumors as
compared to HPV negative cases [21,22]. Balaker and coworkers
concluded in their systematic review that in patients with CUP
of the head and neck, there is no difference in overall survival
between patients who underwent surgery and radiotherapy and
those who had primary radiation or chemoradiation therapy [23].
Other studies support these ﬁndings [22,24]. Given the relatively
low incidence of CUP, randomized trials to determine optimal treat-
ment will be difﬁcult to conduct. However, testing on HPV in these
patients could guide the choice of treatment. In patients with HPV
positive CUP it is likely that the response on treatment will be
similar to that of HPV positive OPSCC and it would be suggestive
for an occult oropharyngeal origin. These patients, based on HPV
testing on cytological material of the nodal metastasis, could be
selected for primary radiotherapy on the neck as well as the ipsi-
lateral oropharynx analogous to the treatment algorithms used for
primary OPSCC.
Of future interest is whether reducing the intensity of (chemo-
)radiotherapy regimens is feasible in patients with HPV-related
HNSCC. However, there is a delicate balance between lowering the
intensity of treatment with the objective to reduce toxicity and the
likelihood of locoregional recurrence or survival [25]. For this rea-
son, it is important that future prospective trials on OPSCC or CUP
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of the head and neck stratify for HPV-status. In this perspective the
possibility of HPV testing on FNAC is highly relevant.
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